

Paper alert

283 Robert E Hurst & Martin Read

Patent alert

287 Emine Abali & Rick Bestwick

Web alert

289 Alick C Stephens

Gene transfer and cell-based therapies

Edited by Terry Hermiston, Walter Günzburg & Leonard W Seymour

- 291 **Walter H Günzburg**
Editorial overview: Oncolytic replicating virus therapy: Is the time right?
- 293 **Philippe Menasché**
The potential of embryonic stem cells to treat heart disease
- 300 **Yue Xu, Preeti Malladi, Diane R Wagner & Michael T Longaker**
Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration
- 306 **Amir S Khan, Patricia A Brown & Ruxandra Draghia-Akli**
Plasmid-based growth hormone-releasing hormone supplementation and its applications
- 317 **Dorota Moroziewicz & Howard L Kaufman**
Gene therapy with poxvirus vectors
- 326 **Edward A Burton, David J Fink & Joseph C Glorioso**
Replication-defective genomic HSV gene therapy vectors: Design, production and CNS applications
- 337 **Steven L Senior & Richard Wade-Martins**
Herpes simplex virus type 1 amplicon vectors for the infectious delivery and expression of genomic DNA loci
- 346 **Uta Griesenbach, Makoto Inoue, Mamoru Hasegawa & Eric WFW Alton**
Sendai virus for gene therapy and vaccination
- 353 **John G Hay**
The potential impact of hypoxia on the success of oncolytic virotherapy
- 359 **Stephen H Thorne, Tae Ho Hwang & David H Kirn**
Vaccinia virus and oncolytic virotherapy of cancer
- 366 **Milan Reiniš**
Technology evaluation: NV-1020, MediGene
- 376 **Tomasz Switaj & Witold Lasek**
Technology evaluation: HYB-2055, Hybridon
- 384 **Bernard Vanhove & Jean-Paul Soullou**
Technology evaluation: Belatacept, Bristol-Myers Squibb
- 394 **Suzanne V Smith**
Technology evaluation: huN901-DM1, ImmunoGen